Cardioprotective effects of lowering oxygen tension after aortic unclamping on cardiopulmonary bypass during coronary artery bypass grafting.
The effect on myocardial reperfusion injury of reducing oxygen tension during reperfusion on cardiopulmonary bypass (CPB) in coronary artery bypass grafting (CABG) was examined at the same time as the influence of diltiazem during CPB was evaluated. A prospective, randomized trial evaluated the hemodynamic and myocardial metabolic recovery in 3 groups of patients undergoing elective CABG; subjects were randomly allocated on the basis of oxygen tension during reperfusion after aortic unclamping: group 1 (n=10) hyperoxic reperfusion (oxygen tension [PO2]=450-550 mmHg); group 2 (n=10): hyperoxic reperfusion and subsequent continuous infusion of diltiazem (0.5 microg/kg); group 3 (n=10): lowering reperfusate PO2 (PO2=200-250 mmHg). Hemodynamic and myocardial metabolic measurements were taken at 6 preset times: before starting the surgical procedure and at 30 min and 3, 9, 21, and 45 h after discontinuation of CPB. The cardiac index in the lowering reperfusate PO2 group was higher than that of the hyperoxic reperfusion groups at 30 min and 3 h after CPB, and malondialdehyde and troponin-T were significantly lower at 30 min and 3 h, respectively. In comparison with the hyperoxic + diltiazem group, the hemodynamic and myocardial recovery in the lowering reperfusate PO2 group was improved for about 3 h after CPB. Reduced oxygen tension during reperfusion after aortic unclamping on CPB is more effective against myocardial injury than a calcium antagonist in the short term. It is a convenient and safe management technique that can reduce morbidity and mortality, especially in the severely compromised heart.
Inoue
Takehiro
T
Department of Cardiovascular Surgery, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan. rtc-ryo@med.kindai.ac.jp
Ku
Kwansong
K
Kaneda
Toshio
T
Zang
Zhiwei
Z
Otaki
Masaki
M
Oku
Hidetaka
H
D000368:Aged; D001011:Aorta / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D003250:Constriction; D001026:Coronary Artery Bypass; D019610:Cytoprotection; D004110:Diltiazem / Q000627:therapeutic use; D004298:Dopamine / Q000008:administration & dosage; D005260:Female; D006321:Heart / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D005996:Nitroglycerin / Q000008:administration & dosage; D010100:Oxygen / Q000378:metabolism*; D010313:Partial Pressure; D011184:Postoperative Period
D002121:Calcium Channel Blockers; D004110:Diltiazem; D005996:Nitroglycerin; D010100:Oxygen; D004298:Dopamine